Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma.
Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Ng HK, Li X, Mu K, Trabelsi S, Brahim DH, Kisljakov AN, Konovalov DM, Moore AS, Carcaboso AM, Sunol M, de Torres C, Cruz O, Mora J, Shats LI, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily MA, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker SJ, Pfister SM, Jones DTW, Fouladi M, von Bueren AO, Baudis M, Resnick A, Jones C. · 2017
Read Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. by Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Ng HK, Li X, Mu K, Trabelsi S, Brahim DH, Kisljakov AN, Konovalov DM, Moore AS, Carcaboso AM, Sunol M, de Torres C, Cruz O, Mora J, Shats LI, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily MA, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker SJ, Pfister SM, Jones DTW, Fouladi M, von Bueren AO, Baudis M, Resnick A, Jones C. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5637314.txt.
Introduction
Mackay and co-authors report a large meta-analysis in Cancer Cell. It covers childhood high-grade glioma and pontine glioma. These brain tumors are rare and incurable. The team pooled 157 new cases with 20 public datasets. The combined set held more than 1,000 cases. Genomic, epigenomic, and gene expression data were analyzed together.
Distinct subgroups emerged around histone mutations. One group paired H3.3G34R/V changes with loss of FBXW7. Another linked H3.3K27M tumors with TOP3A rearrangements. H3.1K27M tumors often carried BCOR mutations. Tumors without histone changes split by other cancer events. Genetic damage rose with patient age. Infants stood out as biologically distinct. The authors offer the scheme as a basis for targeted trials.
Catalog record
| CREATOR | Mackay A, Burford A, Carvalho D, Izquierdo E, Fazal-Salom J, Taylor KR, Bjerke L, Clarke M, Vinci M, Nandhabalan M, Temelso S, Popov S, Molinari V, Raman P, Waanders AJ, Han HJ, Gupta S, Marshall L, Zacharoulis S, Vaidya S, Mandeville HC, Bridges LR, Martin AJ, Al-Sarraj S, Chandler C, Ng HK, Li X, Mu K, Trabelsi S, Brahim DH, Kisljakov AN, Konovalov DM, Moore AS, Carcaboso AM, Sunol M, de Torres C, Cruz O, Mora J, Shats LI, Stavale JN, Bidinotto LT, Reis RM, Entz-Werle N, Farrell M, Cryan J, Crimmins D, Caird J, Pears J, Monje M, Debily MA, Castel D, Grill J, Hawkins C, Nikbakht H, Jabado N, Baker SJ, Pfister SM, Jones DTW, Fouladi M, von Bueren AO, Baudis M, Resnick A, Jones C. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 84 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma By Alan Mackay, Anna Burford, Diana Carvalho, Elisa Izquierdo, Janat Fazal-Salom, Kathryn R Taylor, Lynn Bjerke, Matthew Clarke, Mara Vinci, Meera Nandhabalan, Sara Temelso, Sergey Popov Published in: Cancer Cell DOI: 10.1016/j.ccell.2017.08.017 ABSTRACT Summary We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases. We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors. Genomic aberrations increase with age, highlighting the infant population as biologically and clinically distinct. Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the molecular diversity of the disease, opening up avenues for biological study and providing a basis for functionally defined future treatment stratification. Keywords: genome, exome, methylation, histone, glioblastoma, DIPG SIGNIFICANCE High-grade and diffuse intrinsic pontine glioma in children are rare, incurable brain tumors with differing biology to adult cancers. An integrated genomic, epigenomic and transcriptomic analysis of >1,000 cases across all anatomical compartments of the CNS defines robust clinicopathological and molecular subgroups with distinct biological drivers. As modern classification schemes begin to recognize the diversity of this disease in the pediatric population, we provide a framework for meaningful further subcategorization and identify subgroup-restricted therapeutic targets. INTRODUCTION Pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG) are high-grade glial tumors of children with a median overall survival of 9–15 months, a figure that has remained unmoved for decades (Jones et al., 2012). Although relatively rare in this age group (1.78 per 100,000 population), taken together, gliomas are nonetheless the most common malignant brain tumors in children, and represent the greatest cause of cancer-related deaths under the age of 19 years (Ostrom et al., 2015). Unlike histologically similar lesions in adults, which tend to be restricted to the cerebral hemispheres, diffuse high-grade gliomas in childhood (pHGG) can occur throughout the CNS, with around half occurring in midline locations, in particular the thalamus and the pons (Jones and Baker, 2014), where the lack of available surgical options confers an especially poor prognosis (Kramm et al., 2011). Numerous clinical trials of chemotherapeutics and targeted agents extrapolated from adult GBM studies have failed to show a survival benefit, and more rationally derived approaches based upon an understanding of the childhood diseases are urgently needed (Jones et al., 2016). It has become increasingly apparent that pHGG differ from their adult counterparts, with molecular profiling studies carried out over the last 6–7 years having incrementally identified key genetic and epigenetic differences in pHGG associated with distinct ages of onset, anatomical distribution, clinical outcome, and histopathological and radiological features (Jones and Baker, 2014, Sturm et al., 2014). In particular, the identification of unique recurrent mutations in genes encoding histones H3.3 and H3.1 (Schwartzentruber et al., 2012, Wu et al., 2012) have demonstrated the distinctiveness of the pediatric disease, with the G34R/V and K27M variants appearing to represent different clinicopathological and biological subgroups. This has been recognized by the World Health Organization (WHO) classification of CNS tumors, with the latest version including the novel entity, diffuse midline glioma with H3K27 mutation (Louis et al., 2016). Further refinements incorporating other clearly delineated subsets of the disease in future iterations appear likely and might prove clinically useful. In addition to these uniquely defining histone mutations, detailed molecular profiling has served to identify numerous targets for therapeutic interventions. These include known oncogenes in adult glioma and other tumors with an elevated frequency in the childhood setting (e.g., PDGFRA) (Paugh et al., 2013, Puget et al., 2012) or certain rare histological variants (e.g., BRAF V600E) (Nicolaides et al., 2011, Schiffman et al., 2010), as well as others seemingly unique to DIPG (e.g., ACVR1) (Buczkowicz et al., 2014, Fontebasso et al., 2014, Taylor et al., 2014a, Wu et al., 2014). Future trials will need to exploit these targets, but also incorporate innovative designs that allow for selection of the patient populations within the wide spectrum of disease who are most likely to benefit from any novel agent (Jones et al., 2016). Despite these advances, driven by the efforts of several international collaborative groups to collect and profile these rare tumors, individual publications remain necessarily modestly sized, involving a range of different platforms and analytical techniques. This leaves certain subgroups poorly represented across studies, widely differing individual gene frequencies in different cohorts, and an inability to draw robust conclusions across the whole spectrum of the disease. We have gathered together publicly available data, supplemented with 157 new cases, in order to provide a statistically robust, manually annotated resource cohort of >1,000 such tumors for interrogation. RESULTS Sample Cohort In total, we obtained data from clinically annotated high-grade glioma (WHO, 2007, grade III or IV) or DIPG (radiologically diagnosed, grades II–IV) in 1,067 unique cases (Figure S1A). These were predominantly from children but also included young adults, in order to capture more H3F3A G34R/V mutations, as well as to explore an otherwise under-studied population. There was a median age at diagnosis of 9.8 years, and 982 cases aged 21 years or younger (Table S1). These included 910 taken from 20 published series (Barrow et al., 2011, Bax et al., 2010, Buczkowicz et al., 2014, Carvalho et al., 2014, Castel et al., 2015, Fontebasso et al., 2013, Fontebasso et al., 2014, Grasso et al., 2015, International Cancer Genome Consortium PedBrain Tumor Project, 2016, Khuong-Quang et al., 2012, Korshunov et al., 2015, Paugh et al., 2010, Paugh et al., 2011, Puget et al., 2012, Schwartzentruber et al., 2012, Sturm et al., 2012, Taylor et al., 2014a, Wu et al., 2012, Wu et al., 2014, Zarghooni et al., 2010) and 157 unpublished cases. The vast majority of samples were obtained pre-treatment (biopsy or resection, n = 913), as opposed to post-therapy (relapse or autopsy, n = 146). Samples were classified as occurring within the cerebral hemispheres (n = 482), brainstem (n = 323 in pons, of which 322 were DIPG; three additional cases were in the midbrain and one in the medulla) or other non-brainstem midline locations (n = 224, predominantly thalamus, but also cerebellum, spinal cord, ventricles, and others; referred to as “midline” for simplicity throughout) (Figure 1A). There was a significant association of anatomical location with age of diagnosis, with medians of 13.0 years for hemispheric, 10.0 years for midline, and 6.5 years for DIPG, respectively (p < 0.0001, ANOVA; all pairwise comparisons adjusted p < 0.0001, t test) (Figure 1B), in addition to clinical outcome, with a median overall survival of 18.0 months for hemispheric tumors (2 year overall survival 32%), 13.5 months for midline (2 year overall survival 21.4%), and 10.8 months for DIPG (2 year overall survival 5.2%; p < 0.0001 for all pairwise comparisons, log rank test) (Figure 1C). Children 3 years of age and younger had a markedly improved clinical outcome (p = 0.0028, log rank test), although this benefit was largely restricted to children 1 year and under (n = 40, 2 year survival 61%, p < 0.0001, log